A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS

Reproductive BioMedicine Online

Volumn 15, Issue 3, 2007, Pages 271-279

  Aboulghar, Mohamed ^a,b   Mansour, Ragaa T ^a   Amin, Yahia M ^a   Al Inany, Hesham G ^a,b   Aboulghar, Mona M ^a,b   Serour, Gamal I ^a  

^a Egyptian International Fertility IVF ET Center   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Coasting; GnRH antagonist; High quality embryos; OHSS; Randomized study

Indexed keywords

CHORIONIC GONADOTROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; PROGESTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 34548762590     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60339-2     Document Type: Article

References (26)

1. Aboulghar M 2003 Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Human Reproduction 18, 1140-1141.
2. Aboulghar M, Evers JH, Al-Inany H 2002 Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews No. CD001302 DOI: 10.1002/ 14651858.CD001302.
3. Chen D, Burmeister L, Goldschlag D, Rosenwaks Z 2003 Ovarian hyperstimulation syndrome: strategies for prevention. Reproductive BioMedicine Online 7, 73-79.
4. Consort Group 2001 Revised recommendations for improving the quality of reports of parallel group randomised trials. Journal of the American Medical Association 285, 1987-1991. http://www.consort-statement.org/ [accessed 13 July 2007].
5. D'Angelo A, Amso NN 2002 Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction 17, 2787-2794.
6. Delvigne A, Rozenberg A 2002 Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update 8, 559-577.
7. Erenus M, Zoures C, Rajamahendran P et al. 1991 The effect of embryo quality on subsequent pregnancy rates after in vitro fertilization. Fertility and Sterility 56, 707-710.
8. Garcia-Velasco JA, Isaza V, Quea G, Pellicer A 2006 Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertility and Sterility 85, 547-554.
9. Golan A, Ron-El R, Herman A et al. 1989 Ovarian hyperstimulation syndrome: an update review. Obstetrics and Gynecology Survey 44, 430-440.
10. Gustofson RL, Larsen FW, Bush MR, Segars JH 2006a Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome. Fertility and Sterility 85, 251-254.
11. Gustofson RL, Segars JH, Larsen FW 2006b Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Human Reproduction 21, 2830-2837.
12. Isaza V, Garcia-Velasco JA, Aragonies M et al. 2002 Oocyte and embryo quality after coasting: the experience from oocyte donation. Human Reproduction 17, 1777-1782.
13. Itskovitz-Eldor J, Kol S, Mannaerts B 2000 Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Human Reproduction 15, 1965-1968.
14. Kovacs P, Matyas S, Kaali SG 2006 Effect of coasting on cycle outcome during in vitro fertilization/intracytoplasmic sperm injection cycles in hyper-responders. Fertility and Sterility 85, 913-917.
15. Leung PC, Cheng CK, Zhu XM 2003 Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Molecular and Cellular Endocrinology 202, 145-153.
16. Mannaerts B, Gordon K 2000 Embryo implantation and GnRH antagonists: GnRH antagonists do no activate the GnRH receptor. Human Reproduction 15, 1882-1883.
17. Mansour R 1998 Intracytoplasmic sperm injection: a state of the art technique. Human Reproduction Update 4, 43-56.
18. Mansour R, Aboulghar M, Serour G et al. 2005 Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction 20, 3167-3172.
19. Moretti RM, Marelli MM, Dondi D et al. 1996 Luteinizing hormone-releasing agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. Journal of Clinical Endocrinology and Metabolism 81, 3930-3937.
20. Orvieto R, Tabinson J, Meltser S et al. 2006 Substituting HCG with GnRH agonist to trigger final follicular maturation - a retrospective comparison of three different ovarian stimulation protocols. Reproductive BioMedicine Online 13, 198-201.
21. Rizk B, Aboulghar MA 1991 Modern management of ovarian hyperstimulation syndrome. Human Reproduction 6, 1082-1887.
22. Serour GI, Aboulghar M, Mansour R et al. 1998 Complications of medically assisted conception in 3500 cycles. Fertility and Sterility 4, 638-642.
23. Sher G, Salem R, Feinman M et al. 1993 Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstetrics and Gynecology 81, 1009-1011.
24. Tortoriello DV, McGovern PG, Colon JM, et al. 1998 'Coasting' does not adversely affect cycle outcome in a subset of highly responsive in-vitro fertilization patients. Fertility and Sterility 69, 454-460.
25. Tozer AJ, Iles RK, Iammarrone E et al. 2004 The effects of 'coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Human Reproduction 19, 522-528.
26. Whelan JG III, Vlahos NF 2000 The ovarian hyperstimulation syndrome. Fertility and Sterility 73, 883-896.